World's Best Scientists 2026 revealed!
James N. Ingle

James N. Ingle

D-Index & Metrics

Medicine

D-Index
107
Citations
86567
World Ranking
6089
National Ranking
3262

Overview

James N. Ingle is affiliated with the Mayo Clinic in the United States. Their research primarily focuses on the fields of Biochemistry, Genetics and Molecular Biology, and Medicine. Within these broader areas, their work is specialized in Oncology, Cancer Research, Genetics, Pulmonary and Respiratory Medicine, and Molecular Biology.

Their main research topics include:

  • Estrogen and related hormone effects
  • Breast Cancer Treatment Studies
  • Advanced Breast Cancer Therapies
  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers
  • Cancer-related Molecular Pathways
  • Cancer Cells and Metastasis

James N. Ingle has contributed to multiple scientific publications, with frequent appearances in the following venues:

  • Cancer Research (24 publications)
  • Journal of Clinical Oncology (15 publications)
  • Clinical Cancer Research (12 publications)
  • UNC Libraries (11 publications)
  • npj Breast Cancer (6 publications)

Among their notable recent papers are:

  • "Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14,324 women in 16 trials," 2023, The Lancet
  • "Aurora-A kinase oncogenic signaling mediates TGF-β-induced triple-negative breast cancer plasticity and chemoresistance," 2021, Oncogene
  • "Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer," 2020, JAMA Oncology
  • "Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients," 2020, npj Breast Cancer
  • "Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast Cancer," 2021, Clinical Cancer Research

Throughout their career, James N. Ingle has collaborated frequently with several co-authors, including:

  • Matthew P. Goetz
  • Judy C. Boughey
  • Krishna R. Kalari
  • Roberto A. Leon-Ferre
  • Jodi M. Carter

Best Publications

  • Comprehensive molecular portraits of human breast tumours

    Daniel C. Koboldt;Robert S. Fulton;Michael D. McLellan;Heather Schmidt

  • Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

    Edward H. Romond;Edith A. Perez;John Bryant;Vera J. Suman

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    A Goldhirsch;E P Winer;A S Coates;R D Gelber

  • Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

    C Davies;J Godwin;Richard Gray

  • A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

    Paul E. Goss;James N. Ingle;Silvana Martino;Nicholas J. Robert

  • Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741

    Marc L. Citron;Donald A. Berry;Constance Cirrincione;Clifford Hudis

  • Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009

    Aron Goldhirsch;J. N. Ingle;R. D. Gelber;A. S. Coates

  • Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

    Kathy S Albain;William E Barlow;Steven Shak;Gabriel N Hortobagyi

  • Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer

    I. Craig Henderson;Donald A. Berry;George D. Demetri;Constance T. Cirrincione

  • American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004

    Eric P. Winer;Clifford Hudis;Harold J. Burstein;Antonio C. Wolff

  • Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17

    Paul E. Goss;James N. Ingle;Silvana Martino;Nicholas J. Robert

  • American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer

    Bruce E. Hillner;James N. Ingle;Rowan T. Chlebowski;Julie Gralow

  • Exemestane for Breast-Cancer Prevention in Postmenopausal Women

    Paul E. Goss;James N. Ingle;José E. Alés-Martínez;Angela M. Cheung

  • Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen

    Mitch Dowsett;Jack Cuzick;Jim Ingle;Alan Coates

  • Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes

    Matthew P. Goetz;James M. Rae;Vera J. Suman;Stephanie L. Safgren

  • Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193)

    George W. Sledge;Donna Neuberg;Patricia Bernardo;James N. Ingle

  • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Bernard Asselain;William Barlow;John Bartlett;Jonas Bergh

  • HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

    Daniel F. Hayes;Ann D. Thor;Lynn G. Dressler;Donald Weaver

  • Adjuvant ovarian suppression in premenopausal breast cancer

    Prudence A. Francis;Prudence A. Francis;Meredith M. Regan;Gini F. Fleming;István Láng

  • Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

    Ayca Gucalp;Ayca Gucalp;Sara Tolaney;Steven J. Isakoff;James N. Ingle

Frequent Co-Authors

Matthew P. Goetz
Matthew P. Goetz Mayo Clinic
Vera J. Suman
Vera J. Suman Mayo Clinic
Paul E. Goss
Paul E. Goss Harvard University
Liewei Wang
Liewei Wang Mayo Clinic
Edith A. Perez
Edith A. Perez Mayo Clinic
Daniel J. Schaid
Daniel J. Schaid Mayo Clinic
Kathleen I. Pritchard
Kathleen I. Pritchard University of Toronto
Fergus J. Couch
Fergus J. Couch Mayo Clinic
Nancy E. Davidson
Nancy E. Davidson University of Washington

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring the medical field doesn’t always require a traditional path. Students interested in alternative or flexible options can consider several high-demand careers outside of the classic MD route. For example, those with a bachelor’s degree in a non-nursing major may qualify for direct entry msn programs for non-nursing majors online. These accelerated programs allow individuals to transition into advanced nursing roles quickly.

If you’re looking for accessible entry points to healthcare careers, you might want to review what is the easiest nursing program to get into. Some schools offer lower barriers to entry, supporting diverse applicant backgrounds.

For those interested in medical administration or remote work, check out the best online medical billing and coding schools. These programs typically take less time to complete and can lead to rewarding careers in healthcare data.

Additionally, future licensed practical nurses (LPNs) may choose an lpn program without teas test or other entrance exam requirements, making healthcare education more accessible. Many pathways exist to join the growing U.S. healthcare workforce—find the one that fits your goals and lifestyle.

Best Scientists Citing James N. Ingle

Trending Scientists

Recently Published Articles